Now Available: France Pharmaceuticals & Healthcare Report Q1 2015

From: Fast Market Research, Inc.
Published: Thu Dec 25 2014

Despite the French government partial ly abandoning fiscal deficit targets in its 2015 budget, cost - containment measures will continue to weigh on the pharmaceuticals and healthcare sector for the foreseeable future . The government's strategy of emphasis ing preventive care and improved access to doctors will likely avoid long-term costs by reducing the burden or risks associated with unchecked conditions . Meanwhile, it will also sustain access to medicines, including prescription drug s, provided that French healthcare and medicine consumption patterns remain high.

Full Report Details at

Headline Expenditure Projections

* Pharmaceuticals: EUR33.94bn (USD44.80bn) in 2013 to EUR33.06bn (USD44.29bn) in 2014; -2.6% in local currency terms and -1.1% in US dollar terms.
* Healthcare: EUR245.28bn (USD323.77bn) in 2013 to EUR252.33bn (USD338.13bn) in 2014; +2.9% in local currency terms and 4.4% in US dollar terms.

Risk/Reward Index

In Q115 France maintains an overall Risk/Reward Index (RRI) score of 71.7 out of the maximum 100 points. However, this has shifted downward the country's ranking position in terms of attractiveness to pharmaceutical investors from third in Q414 to fourth in Q115 out of 15 markets in Western Europe. An upward revision to the UK market score is the main driver underlying ranking variation. The French market Rewards' indices, including market growth rate, remain less attractive than its Risk score.

Key Trends And Developments


* Multinational drugmaker Sanofi reported Q314 yearly financial data: a 5.1% increase in revenues to EUR8.78bn (USD14.14bn), a 9.4% increase in net income to EUR1.94bn (USD3.13bn) and a 10.3% increase in earnings per share to EUR1.47 (2.37USD) - boosted by the favourable impact of vaccine (+11.2%), animal health (+12.7%) and Genzyme (+24.6%) sales. However, investor sentiment sank following the company's announcement that growth of its diabetes treatments (accounting for a fifth of...

The France Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's France Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the French pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for France to test other views - a key input for successful budgeting and strategic business planning in the French pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Peru Pharmaceuticals & Healthcare Report Q1 2015
- Lebanon Pharmaceuticals & Healthcare Report Q1 2015
- Turkey Pharmaceuticals & Healthcare Report Q1 2015
- India Pharmaceuticals & Healthcare Report Q1 2015
- Slovenia Pharmaceuticals & Healthcare Report Q1 2015
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »